GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (MIL:1BMRN) » Definitions » Pre-Tax Income

Biomarin Pharmaceutical (MIL:1BMRN) Pre-Tax Income : €219 Mil (TTM As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Biomarin Pharmaceutical Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Biomarin Pharmaceutical's pretax income for the three months ended in Mar. 2024 was €97 Mil. Its pretax income for the trailing twelve months (TTM) ended in Mar. 2024 was €219 Mil. Biomarin Pharmaceutical's pretax margin was 16.27%.

During the past 13 years, Biomarin Pharmaceutical's highest Pretax Margin was 9.60%. The lowest was -74.41%. And the median was -4.82%.


Biomarin Pharmaceutical Pre-Tax Income Historical Data

The historical data trend for Biomarin Pharmaceutical's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical Pre-Tax Income Chart

Biomarin Pharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Pre-Tax Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -85.33 -40.28 -66.69 141.20 172.91

Biomarin Pharmaceutical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Pre-Tax Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 53.01 65.36 39.04 17.72 97.10

Competitive Comparison of Biomarin Pharmaceutical's Pre-Tax Income

For the Biotechnology subindustry, Biomarin Pharmaceutical's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomarin Pharmaceutical's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biomarin Pharmaceutical's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Biomarin Pharmaceutical's Pre-Tax Income falls into.



Biomarin Pharmaceutical Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Biomarin Pharmaceutical's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=144.977+-9.663+-15.351+53.497+-0.548
=173

Biomarin Pharmaceutical's Pretax Income for the quarter that ended in Mar. 2024 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=72.185+10.366+-3.263+17.816+-0.0010000000000048
=97

Pre-Tax Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €219 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biomarin Pharmaceutical  (MIL:1BMRN) Pre-Tax Income Explanation

Biomarin Pharmaceutical's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as

Pretax Margin=Pretax Income/Revenue
=97.103/596.926
=16.27%

During the past 13 years, Biomarin Pharmaceutical's highest Pretax Margin was 9.60%. The lowest was -74.41%. And the median was -4.82%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biomarin Pharmaceutical Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Biomarin Pharmaceutical's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomarin Pharmaceutical (MIL:1BMRN) Business Description

Traded in Other Exchanges
Address
770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the U.S. in 2023.

Biomarin Pharmaceutical (MIL:1BMRN) Headlines

No Headlines